ArticleCellular and molecular life sciences : CMLS2010
The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.
Article in Cellular and molecular life sciences : CMLS, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- The landscape of prognostic and immunological role of myosin light chain 9 (MYL9) in human tumors.Immunity, inflammation and disease · 2022Article
- Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation.Cell death & disease · 2019Article
- Podocyte histone deacetylase activity regulates murine and human glomerular diseases.The Journal of clinical investigation · 2019Article
- Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma.PloS one · 2017Article
- Myosin-X and disease.Experimental cell research · 2015Review
- Computational identification of surrogate genes for prostate cancer phases using machine learning and molecular network analysis.Theoretical biology & medical modelling · 2014Article
- Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis.British journal of cancer · 2014Article
- Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.The Journal of clinical investigation · 2014Article
- Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.Molecular & cellular proteomics : MCP · 2014Article
- Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling.Cell communication and signaling : CCS · 2013Article
- EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
- Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis.The Journal of investigative dermatology · 2011Article
- Elevated MYO10 Predicts Poor Prognosis and its Deletion Hampers Proliferation and Migration Potentials of Cells Through Rewiring PI3K/Akt Signaling in Cervical Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic spreading of cancer cells is a highly complex process directed primarily by the interplay between tumor microenvironment, cell surface receptors, and actin cytoskeleton dynamics. To advance our understanding of metastatic cancer dissemination, we have developed a model system that is based on two v-src transformed chicken sarcoma cell lines-the highly metastatic parental PR9692 and a non-metastasizing but fully tumorigenic clonal derivative PR9692-E9. Oligonucleotide microarray analysis of both cell lines revealed that the gene encoding the transcription factor EGR1 was downregulated in the non-metastatic PR9692-E9 cells. Further investigation demonstrated that the introduction of exogenous EGR1 into PR9692-E9 cells restored their metastatic potential to a level indistinguishable from parental PR9692 cells. Microarray analysis of EGR1 reconstituted cells revealed the activation of genes that are crucial for actin cytoskeleton contractility (MYL9), filopodia formation (MYO10), the production of specific extracellular matrix components (HAS2, COL6A1-3) and other essential pro-metastatic abilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.